Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate

September 11, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company’s universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of …

Genocea Presents Phase 1 Immunology Data for Novel Pneumoccocus Vaccine at ICAAC

GEN-004 Shown to Induce Antibody and TH17 Responses September 6, 2014 Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today presented data from a Phase 1 study of GEN-004, an investigational vaccine designed to prevent disease caused by all serotypes of pneumococcus (Streptococcus pneumoniae) The poster (G-291), titled “Safety and Immunogenicity of a Novel Lipidated Protein …

Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004

June 23, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line results from a Phase 1 study of GEN-004, an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. The Phase 1 study met its safety, tolerability and …

Interactive Map: Advance market commitment for pneumococcal vaccines

This map shows the availability of pneumococcal vaccines PCV10 and PCV13 through the Advanced Market Commitment scheme designed to get life saving vaccines to the developing world as fast and reliably as possible. *Source: Advance Market Commitment for Pnewumococcal Vaccines, Annual Report 1 April 2013 – 31 March 2014, prepared by the GAVI Alliance Click here to see our Advance …

Pfizer unveil results of Prevnar 13 Phase 3 study in adults with HIV

Pfizer have unveiled the results from a Phase 3 study that trialled pneumococcal vaccine Prevnar 13 in adults infected with human immunodeficiency virus (HIV). In the Phase 3, open-label, single-arm trial, 331 HIV-infected individuals aged 18 years and older who had previously received at least one dose of pneumococcal polysaccharide vaccine (PSSV) were given three doses of Prevnar 13 at …